Symptomatic effect of selegiline in de novo parkinsonian patients
- 1 January 1993
- journal article
- clinical trial
- Published by Wiley in Movement Disorders
- Vol. 8 (S1), S36-S40
- https://doi.org/10.1002/mds.870080508
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Selegiline in de novo parkinsonian patients: The French selegiline multicenter trial (FSMT)Acta Neurologica Scandinavica, 1991
- Parkinson's disease: pathophysiologyThe Lancet, 1991
- Effect of Deprenyl on the Progression of Disability in Early Parkinson's DiseaseNew England Journal of Medicine, 1989
- The pharmacology of selegiline ((−)deprenyl). New aspectsActa Neurologica Scandinavica, 1989
- Oxidants and the central nervous system: some fundamental questions. Is oxidant damage relevant to Parkinson's disease, Alzheimer's disease, traumatic injury or stroke?Acta Neurologica Scandinavica, 1989
- Selegiline as primary treatment in early phase Parkinson's disease - an interim reportActa Neurologica Scandinavica, 1989
- DATATOP: A Multicenter Controlled Clinical Trial in Early Parkinson's DiseaseArchives of Neurology, 1989
- A Selective Increase in Particulate Superoxide Dismutase Activity in Parkinsonian Substantia NigraJournal of Neurochemistry, 1989
- The Effect of Deprenyl (Selegiline) on the Natural History of Parkinson's DiseaseScience, 1989
- Monoamine Oxidase Activity and Monoamine Metabolism in Brains of Parkinsonian Patients Treated with l‐DeprenylJournal of Neurochemistry, 1986